Drug intelligence / Profile preview

TNK04

Development stage: Preclinical
Lead developer: SynoCare
Modality: Small Molecules
Administration: Oral

Overview

TNK04 is a preclinical-stage small molecule therapeutic being developed by SynoCare. It is part of the company's RNA-targeting small molecule platform, which aims to modulate disease-relevant RNA structures or functions. While the specific molecular target (designated as TNK04XX) remains undisclosed, the program is primarily focused on the treatment of solid tumors. The platform strategy also encompasses potential applications in autoimmune and inflammatory diseases.

Beyond the preview

Go deeper on TNK04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNK04.

Explore the full profile